Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb:6:233-237.
doi: 10.1200/JGO.19.00366.

Quadruple-Negative Breast Cancer: An Uneven Playing Field

Geetanjali Saini  1 , Shristi Bhattarai  1 , Keerthi Gogineni  2 , Ritu Aneja  1
Affiliations

Quadruple-Negative Breast Cancer: An Uneven Playing Field

Geetanjali Saini et al. JCO Glob Oncol. 2020 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Keerthi Gogineni

Honoraria: Pfizer, Eli Lilly

Research Funding: Pfizer (Inst), Calithera Biosciences (Inst), Merck (Inst)

Travel, Accommodations, Expenses: Eli Lilly

No other potential conflicts of interest were reported.

Figures

FIG 1
FIG 1
Triple-negative breast cancers (TNBCs) make up a highly heterogeneous group that can be classified variously, as outlined in the long columns (data adapted-). Quadruple-negative breast cancer (QNBC) is clinically defined as an androgen receptor (AR)–negative TNBC and is briefly characterized in the lower half of the schematic. There is a pressing need to extricate QNBC from the shadows of TNBC and classify it as a unique, clinically relevant BC subtype. AA, African American; BL, basal-like; BLIA, basal-like immune associated; BLIS, basal-like immune suppressed; CDK4/6i, CDK4/6 inhibitors; IHC, immunohistochemistry; IM, immunomodulatory; LAR, luminal androgen receptor; M, mesenchymal; ML, mesenchymal stem-like; PARPi, PARP inhibitor; PI3Ki, PI3K inhibitor.
See this image and copyright information in PMC

References

    1. Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: Improving patient selection for treatment. Cancer Discov. 2019;9:176–198. - PMC - PubMed
    1. Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21:1688–1698. - PMC - PubMed
    1. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–2767. - PMC - PubMed
    1. Prado-Vázquez G, Gámez-Pozo A, Trilla-Fuertes L, et al. A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses. Sci Rep. 2019;9:1538. - PMC - PubMed
    1. Santonja A, Sánchez-Muñoz A, Lluch A, et al. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. Oncotarget. 2018;9:26406–26416. - PMC - PubMed

Publication types

MeSH terms